NCT05700903 2026-03-02
ARCH
University of Colorado, Denver
Phase 4 Completed
Clinical Trials
57 trialsNCT03070886 2026-01-14
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NRG Oncology
Phase 2/3 Completed
NCT05122377 2026-01-06
RWE About QOL and Compliance of Patients With OFS in China
Fudan University
Completed
NCT00328614 2025-05-16
Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
Thomas Jefferson University
Phase 1 Completed
NCT02278185 2025-05-11
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
Phase 2 Completed
NCT02366494 2024-11-25
Micro RNAs to Predict Response to Androgen Deprivation Therapy
Medical College of Wisconsin
Completed
NCT05163106 2024-08-02
NEOLETRIB
University Hospital, Akershus
Phase 2 Completed
NCT03007979 2024-03-20
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Washington University School of Medicine
Phase 2 Completed
NCT00099086 2024-01-31
Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
Medical University of South Carolina
Phase 1 Completed
NCT00482807 2023-11-24
Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer
University of Nebraska
Phase 1 Completed
NCT00541047 2023-11-13
RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
University College, London
Phase 3 Completed
NCT00002889 2023-08-18
Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT03447132 2023-03-10
SAFIA
International Cancer Research Group, United Arab Emirates
Phase 3 Completed
NCT00055731 2023-01-18
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
UNICANCER
Phase 3 Completed
NCT02064036 2022-10-18
CCRO025
University of California, Davis
Phase 1 Completed
NCT02789878 2022-09-15
Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer
Instituto do Cancer do Estado de São Paulo
Phase 2 Completed
NCT01989780 2022-08-04
BOOSTER
Japan Breast Cancer Research Group
Phase 2 Completed
NCT02586675 2022-01-21
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00116220 2022-01-06
Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer
Dana-Farber Cancer Institute
Phase 3 Completed
NCT02867020 2021-07-07
Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels
Latin American Cooperative Oncology Group
Phase 2 Completed
NCT02518191 2021-06-11
Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Phase 3 Completed
NCT04060043 2021-05-10
Pilot Study to Evaluate the Effects of a Generic Goserelin Acetate in Patients With Prostate Cancer
CMX Research
Phase EARLY_PHASE1 Completed
NCT00104715 2021-02-21
Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer
UNICANCER
Phase 3 Completed
NCT02059213 2020-09-16
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00186121 2019-10-07
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
Stanford University
Phase 2 Completed
NCT00669162 2019-07-24
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
University of Kansas Medical Center
Phase 1/2 Completed
NCT01638247 2018-09-19
MALE
GBG Forschungs GmbH
Phase 3 Completed
NCT00298155 2018-08-09
TAPS
University of Washington
Phase 2 Completed
NCT00283803 2018-08-07
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
University of Washington
Phase 2 Completed
NCT00165399 2018-06-25
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00423475 2018-05-17
Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer
UNICANCER
Phase 3 Completed
NCT02483767 2017-10-17
POF
Peking Union Medical College Hospital
Phase 3 Completed
NCT01023061 2017-06-06
RAD1
University of Washington
Phase 2 Completed
NCT00225420 2017-06-01
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Completed
NCT00658697 2017-05-25
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00769795 2017-03-29
Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
University of Washington
Phase 2 Completed
NCT01750398 2016-12-05
BAT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00081159 2016-11-10
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01076335 2016-09-19
Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00439751 2016-07-12
ELAAT
Ontario Clinical Oncology Group (OCOG)
Phase 3 Completed
NCT00016913 2016-07-06
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00586898 2016-03-25
Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00010010 2016-03-11
Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer
NYU Langone Health
Phase 2 Completed
NCT01530607 2016-02-25
Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
King Faisal Specialist Hospital & Research Center
Phase 3 Completed
NCT00067015 2015-12-22
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT00500110 2015-04-28
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00631527 2015-01-29
Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01250717 2014-02-04
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00003394 2013-06-24
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00012090 2013-06-18
Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum
Memorial Sloan Kettering Cancer Center
Phase 2 Completed